irinotecan has been researched along with Bone Neoplasms in 54 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.85) | 18.2507 |
| 2000's | 25 (46.30) | 29.6817 |
| 2010's | 21 (38.89) | 24.3611 |
| 2020's | 7 (12.96) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Ding, K; Kang, S; McEachern, D; Miller, R; Nikolovska-Coleska, Z; Qin, D; Qiu, S; Shangary, S; Wang, G; Wang, S; Yang, D; Yu, S | 1 |
| Ahmed, MA; Basaran, M; Dogan, I; Iribas, A | 1 |
| Carrabotta, M; Cristalli, C; Donati, DM; Ferracin, M; Giusti, V; Ianzano, ML; Landuzzi, L; Lollini, PL; Magnani, M; Manara, MC; Nanni, P; Nicoletti, G; Palladini, A; Parra, A; Pasello, M; Picci, P; Righi, A; Ruzzi, F; Scotlandi, K | 1 |
| Brohl, AS; Cubitt, CL; Fridley, B; Kahen, E; Reed, DR; Welch, D | 1 |
| Aranda, E; Balbín, M; Bando, I; Bellosillo, B; Calle, SG; Díaz-Rubio, E; García-Alfonso, P; Llovet, P; Lopez, C; Martínez, A; Mediero, B; Moral, VM; Orden, V; Ortiz-Morales, MJ; Palanca, S; Peligros Gomez, MI; Quintero, G; Salud, A; Sastre, J; Viéitez, JM | 1 |
| Balaguer-Lluna, L; Burgueño, V; Carcaboso, AM; Castañeda, A; Castillo-Ecija, H; Cuadrado-Vilanova, M; de Alava, E; Garcia-Dominguez, DJ; Gomez-Gonzalez, S; Hontecillas-Prieto, L; Lavarino, C; Monterrubio, C; Mora, J; Olaciregui, NG; Paco, S; Pascual-Pasto, G; Perez-Jaume, S; Resa-Pares, C; Restrepo-Perdomo, C; Roldan, M; Santa-Maria, V; Suñol, M; Vila-Ubach, M | 1 |
| Li, Y; Qu, J; Zhang, P; Zhang, Z | 1 |
| Abuhijla, F; Abuhijlih, R; Alnsour, A; Halalsheh, H; Ismail, T; Khozouz, O; Lewin, J; Salah, S; Shahin, O; Sultan, I; To, YH; Yaser, S | 1 |
| Duan, L; Jiang, J; Liu, T; Mu, X; Shao, P; Yan, J; Zhang, F; Zhang, M | 1 |
| Ju, HY; Kang, HG; Kim, JH; Lee, JA; Park, BK; Park, HJ; Park, M; Park, SY; Yang, HC | 1 |
| Naviglio, S; Rabusin, M | 1 |
| Büyükkapu Bay, S; Çakır, FB; Darendeliler, E; Görgün, O; Kebudi, R; Zülfikar, B | 1 |
| Cai, X; Chen, H; Cheng, Y; He, X; Huang, Q; Li, Y; Lin, K; Wang, Y; Xiao, J; Zhang, Q; Zou, Y | 1 |
| Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N | 1 |
| Hendel, HW; Jensen, BV; Nielsen, D; Skougaard, K | 1 |
| Morland, B; Platt, K; Whelan, JS | 1 |
| Joo, J; Kwon, MM; Lim, KY; Park, BK; Park, HJ; Park, SY; Yoon, JH | 1 |
| Cho, JM; Go, SI; Jeon, KN; Kang, JH; Kang, MH; Kim, HG; Kim, MJ; Lee, A; Lee, GW; Lee, JH; Lee, US; Lee, WS | 1 |
| Atasoy, A; Babacan, NA; Cihan, S; Kos, TF; Yildirim, Y | 1 |
| Battiste, JD; Bonney, PA; Maurer, AJ; McNall-Knapp, RY; Santucci, JA; Sughrue, ME | 1 |
| Motoshita, J; Nakagawa, T; Nakano, T; Nakashima, T; Okabe, M; Shiratsuchi, H; Tamae, A; Tanaka, R; Yasumatsu, R | 1 |
| Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E | 1 |
| Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M | 1 |
| Burris, HA; Farley, C; Greco, FA; Hainsworth, JD; Murphy, PB; Saez, RA; Spigel, DR; Yardley, DA; Zubkus, JD | 1 |
| Arcamone, G; Bisogno, G; Carli, M; Miglionico, L; Riccardi, R; Scagnellato, A | 1 |
| Kitagawa, M; Koh, T; Kondo, Y; Nakagawa, N; Nanri, M; Oguro, A; Yamasaki, J | 1 |
| Cho, EK; Jung, SH; Kim, YS; Kyung, SY; Lee, JH; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ | 1 |
| Abbas, A; Bekaii-Saab, T; Burak, W; Lustberg, MB; Lustberg, ME; McCracken-Bussa, B; Otterson, G; Villalona-Calero, MA; Young, D | 1 |
| Ebi, N; Goto, I; Imamura, F; Iwamoto, Y; Kobayashi, M; Matsui, K; Nakagawa, K; Oizumi, S; Saito, H; Saka, H; Sawa, T; Seki, N; Shibata, K; Takeda, K | 1 |
| Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW | 1 |
| Hayashi, H; Masuda, N; Miyazaki, M; Morinaga, R; Nakagawa, K; Nakayama, T; Nishida, Y; Okamoto, I; Okamoto, W; Sakamoto, J; Satoh, T; Terashima, M; Tokunaga, Y; Tominaga, S; Tsurutani, J; Yamaguchi, M | 1 |
| Cho, YJ; Duk Lee, J; Go, SI; Hwang, YS; Jeong, YY; Kim, DC; Kim, HC; Ko, GH; Lee, GW; Lee, JH; Lee, JS; Oh, S; Yang, JW | 1 |
| Chiba, H; Hirayama, Y; Iyama, S; Niitsu, Y; Oku, T; Sagawa, T; Sakamaki, S; Sato, Y; Takahashi, M; Takayama, T; Takayanagi, N; Tsuji, Y | 1 |
| Akiyama, T; Doi, T; Hirata, K; Homma, H; Iyama, S; Kida, M; Kogawa, K; Mezawa, S; Murakami, K; Murase, K | 1 |
| Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H | 1 |
| Buchdunger, E; Germain, GS; Harwood, FC; Houghton, PJ; Schuetz, JD; Stewart, CF; Traxler, P | 1 |
| Akbulut, H; Buyukcelik, A; Demirkazik, A; Icli, F; Onur, H; Utkan, G; Yalcin, B | 1 |
| Cheshire, PJ; Daw, N; Germain, GS; Gilbertson, R; Harwood, FC; Houghton, PJ; Jenkins, JJ; Leggas, M; Panetta, JC; Peterson, J; Schuetz, JD; Stewart, CF | 1 |
| Arima, T; Horino, K; Inoue, M; Kaneda, H; Kimura, M; Kuhara, H; Kume, S; Nakano, M; Nishimura, T; Uemura, K | 1 |
| Kosmas, Ch; Malamos, NA; Pergantas, N; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Tsavdaridis, D; Xynotroulas, J | 1 |
| Bamias, A; Briasoulis, E; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Kosmidis, P; Makatsoris, T; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Brodsky, I; Rosenbluth, JZ; Styler, MJ; Zak, D | 1 |
| Fujii, Y; Kobayashi, T; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T | 1 |
| Albritton, K; Goldsby, RE; McAllister, N; McCarville, MB; McNall-Knapp, RY; Rausen, AR; Wagner, LM | 1 |
| Katakami, N | 1 |
| Ahn, JS; Ahn, MJ; Hong, YS; Hwang, IG; Lee, HR; Lee, J; Lee, SC; Lim, HY; Park, BB; Park, K; Park, S | 1 |
| Arakawa, K; Hamada, K; Kashiwabara, K; Kawate, S; Morishita, Y; Ohwada, S; Sunose, Y; Takeyoshi, I; Tohgo, N; Toya, H; Tsutsumi, H | 1 |
| Crassard, N; Frappaz, D; Marec-Bérard, P; Philip, T; Ranchin, B; Schell, M; Thiesse, P | 1 |
| Akerley, W; Atkins, JN; Bearden, JD; Chansky, K; Crowley, JJ; Gandara, DR; Goodwin, JW; Hesketh, PJ; McCoy, J | 1 |
| Doihara, H; Takashima, S; Yokoyama, N | 1 |
| Ikeda, H; Koshiba, R | 1 |
| Baz, DV; Bofill, JS; Nogueira, JA | 1 |
| Bissery, MC; D'Attino, RM; Filipski, E; Garufi, C; Granda, TG; Lévi, F; Terzoli, E; Vrignaud, P | 1 |
| Calleja, E; Cosetti, M; Gerald, W; Gorlick, R; Healey, JH; Huvos, AG; LaQuaglia, M; Meyers, PA; Trippett, T; Wexler, LH | 1 |
4 review(s) available for irinotecan and Bone Neoplasms
| Article | Year |
|---|---|
Primary combined small cell carcinoma and squamous cell carcinoma of the oropharynx with special reference to EGFR status of small cell carcinoma component: Case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; ErbB Receptors; Fatal Outcome; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasms, Complex and Mixed; Oropharyngeal Neoplasms; Otorhinolaryngologic Surgical Procedures | 2017 |
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Femoral Neoplasms; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Osteosarcoma; Palliative Care; Salvage Therapy; Scalp; Skin Neoplasms; Thoracotomy | 2005 |
Irinotecan-induced dysarthria.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aphasia, Broca; Bone Neoplasms; Camptothecin; Dysarthria; Enzyme Inhibitors; Fatal Outcome; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Organoplatinum Compounds; Oxaliplatin; Premedication; Sigmoid Neoplasms | 2001 |
Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Diarrhea; Drug Evaluation; Enzyme Inhibitors; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neuroectodermal Tumors, Primitive; New York City; Osteosarcoma; Retrospective Studies; Rhabdomyosarcoma; Sarcoma, Ewing; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
15 trial(s) available for irinotecan and Bone Neoplasms
| Article | Year |
|---|---|
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Bone Neoplasms; Camptothecin; Cell Count; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Microsatellite Instability; Middle Aged; Mutation; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins B-raf; ras Proteins; Risk Assessment; Young Adult | 2020 |
Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cetuximab; Colorectal Neoplasms; Denmark; Digestive System Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Outcome Assessment, Health Care; Positron-Emission Tomography; Prevalence; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
A phase II window study of irinotecan (CPT-11) in high risk Ewing sarcoma: a Euro-E.W.I.N.G. study.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Camptothecin; Child; Humans; Irinotecan; Risk; Sarcoma, Ewing | 2014 |
A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Prospective Studies; Sarcoma, Ewing; Taxoids; Young Adult | 2014 |
Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate; Tegafur; Tissue Distribution; Treatment Outcome | 2009 |
Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Carboplatin; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2009 |
Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Treatment Outcome | 2011 |
Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Camptothecin; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Salvage Therapy; Topoisomerase Inhibitors; Young Adult | 2013 |
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neutropenia; Taxoids | 2005 |
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis | 2005 |
Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Treatment Outcome | 2006 |
Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2007 |
[A pilot study of irinotecan hydrochloride for metastatic breast cancer--efficacy as a salvage therapy].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Irinotecan; Lymphatic Metastasis; Middle Aged; Pilot Projects; Salvage Therapy | 2000 |
35 other study(ies) available for irinotecan and Bone Neoplasms
| Article | Year |
|---|---|
Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Bone Neoplasms; Cell Line, Tumor; Drug Design; HCT116 Cells; Humans; Indoles; Mice; Morpholines; Osteosarcoma; Piperazines; Proto-Oncogene Proteins c-mdm2; Rats; Spiro Compounds; Structure-Activity Relationship; Tumor Suppressor Protein p53 | 2009 |
Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Dacarbazine; Humans; Irinotecan; Retrospective Studies; Sarcoma, Ewing; Temozolomide; Vincristine | 2023 |
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
Topics: 12E7 Antigen; Animals; Antibodies; Antineoplastic Agents; Bone Neoplasms; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Osteosarcoma; Sarcoma, Ewing; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2019 |
Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cyclophosphamide; Depsipeptides; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Etoposide; Histone Deacetylase Inhibitors; Histone Deacetylases; Histone Demethylases; Humans; Hydrazines; Irinotecan; Sarcoma, Ewing; Sulfonamides; Vincristine | 2019 |
Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution.
Topics: Adolescent; Animals; Antineoplastic Agents; Bone Neoplasms; Humans; Irinotecan; Mice; Pharmaceutical Preparations; Sarcoma, Ewing | 2020 |
Reduction-responsive sulfur dioxide polymer prodrug nanoparticles loaded with irinotecan for combination osteosarcoma therapy.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Female; Humans; Irinotecan; Mice, Inbred BALB C; Micelles; Nanoparticles; Osteosarcoma; Oxidation-Reduction; Polymers; Prodrugs; Sulfur Dioxide; Topoisomerase I Inhibitors | 2020 |
Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Diarrhea; Disease Progression; Drug Administration Schedule; Humans; Irinotecan; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Salvage Therapy; Sarcoma, Ewing; Temozolomide | 2021 |
Polydopamine Nanoparticles Camouflaged by Stem Cell Membranes for Synergistic Chemo-Photothermal Therapy of Malignant Bone Tumors.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Bone Neoplasms; Cell Line, Tumor; Cell Membrane; Drug Liberation; Female; Humans; Immune Evasion; Indoles; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Photothermal Therapy; Polymers; RAW 264.7 Cells; Stem Cells; Tissue Distribution | 2020 |
Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Female; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Osteosarcoma; Retrospective Studies; Sarcoma, Ewing; Temozolomide; Vincristine; Young Adult | 2022 |
Irinotecan-induced muscular contractions.
Topics: Abdominal Muscles; Administration, Intravenous; Administration, Oral; Adolescent; Bone Neoplasms; Humans; Irinotecan; Male; Muscle Contraction; Sarcoma, Ewing; Temozolomide | 2018 |
Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Neuroblastoma; Osteosarcoma; Remission Induction; Retreatment; Rhabdomyosarcoma; Sarcoma, Ewing; Survival Rate; Temozolomide; Vincristine; Wilms Tumor | 2019 |
Multifunctional melanin-like nanoparticles for bone-targeted chemo-photothermal therapy of malignant bone tumors and osteolysis.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Cells, Cultured; Combined Modality Therapy; Durapatite; Heterografts; Hyperthermia, Induced; Indoles; Infrared Rays; Irinotecan; Melanins; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Osteolysis; Phototherapy; Polymers; Tissue Distribution | 2018 |
Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.
Topics: Adolescent; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Irinotecan; Male; Mice, Nude; Osteosarcoma; Topoisomerase I Inhibitors; Trabectedin | 2019 |
Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Magnetic Resonance Imaging; Middle Aged; Pelvic Bones; Positron-Emission Tomography; Recurrence; Taxoids; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Hypersensitivity and tumor lysis syndrome associated with cetuximab treatment: should we be afraid?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Neoplasms; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Hypersensitivity; Emergency Treatment; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome; Tumor Lysis Syndrome | 2015 |
Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Cerebellar Neoplasms; Dacarbazine; Female; Humans; Irinotecan; Medulloblastoma; Temozolomide; Young Adult | 2016 |
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pleural Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
No effect of irinotecan in patients with resistant desmoplastic small round cell tumor.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Fibroma, Desmoplastic; Humans; Irinotecan; Male; Prognosis; Sarcoma, Small Cell | 2010 |
[A case of S-1-resistant gastric cancer with multiple bone metastases and disseminated intravascular coagulation--effective treatment by combined chemotherapy with CDDP and CPT-11].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Disseminated Intravascular Coagulation; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Child; Child, Preschool; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infant; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Follow-Up Studies; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
[A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Chronotherapy; Colonic Neoplasms; Drug Evaluation; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin | 2003 |
[A case of gastric carcinoma with multiple skin, bone, and bilateral ovary metastasis; effective treatment by chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Ovarian Neoplasms; Prognosis; Quality of Life; Skin Neoplasms; Stomach Neoplasms | 2003 |
[A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pleurisy; Quality of Life; Tegafur; Uracil | 2004 |
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Irinotecan; Neoplasm Proteins; Osteosarcoma; Piperazines; Pyrimidines; Topotecan | 2004 |
Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2004 |
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Proteins; Osteosarcoma; Quinazolines; Xenograft Model Antitumor Assays | 2004 |
[A case of recurrent breast cancer with bone metastasis causing pancytopenia--efficacy of low-dose CPT-11+ MPA].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Mastectomy, Segmental; Medroxyprogesterone Acetate; Middle Aged; Pancytopenia; Quality of Life | 2005 |
[A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged; Tegafur; Uracil | 2005 |
Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Child; Dacarbazine; Female; Humans; Injections, Intravenous; Irinotecan; Male; Neoplasm Metastasis; Sarcoma, Ewing; Temozolomide | 2007 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
[A recurrent endocrine cell cancer of the stomach showing almost complete remission after chemotherapy for 1 year].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Remission Induction; Stomach Neoplasms | 2006 |
Osteosarcoma metastatic to the kidney and iatrogenic hemorrhage.
Topics: Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Bone Neoplasms; Calcinosis; Camptothecin; Child; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Hematuria; Hemorrhage; Humans; Iatrogenic Disease; Ilium; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Methotrexate; Osteosarcoma; Radiography; Tibia; Ultrasonography, Interventional | 2008 |
[Four cases of recurrent breast cancer effectively treated by the new antitumor agent, CPT-11 (irinotecan)].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lymphatic Metastasis; Mastectomy, Radical; Middle Aged; Soft Tissue Neoplasms | 1994 |
Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; Camptothecin; Drug Administration Schedule; Irinotecan; Male; Mice; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin | 2002 |